Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Media
News and announcements
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
11/02/2022
Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer
28/12/2021
Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
15/12/2021
Vaccibody AS – Notice of Extraordinary General Meeting
15/12/2021
New chairman at Nykode Therapeutics as the Company enters a new stage of internationalization
30/11/2021
Minutes of Extraordinary General Meeting
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer